STRATIPATH

AI-BASED PRECISION DIAGNOSTICS TO IMPROVE CANCER TREATMENT DECISIONS AND PATIENT OUTCOMES

Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and improving patient outcomes by assisting physicians in delivering optimal treatment to every patient. Stratipath’s pioneering solutions transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development.

The Challenge – Complex Treatment Decisions Leading to Under and Overtreatment of Patients

Cancer remains a leading global cause of death and economic burden. As treatment options continue to expand, clinicians face increasingly complex decisions when determining optimal treatment strategies for individual patients.

Another critical diagnostic challenge is the high prevalence of inconclusive diagnoses. For example, over 50% of breast cancers are currently categorised as intermediate risk. This diagnostic uncertainty raises the risk of undertreatment, potentially leading to relapse, or overtreatment, resulting in unnecessary and potentially harmful side effects. Genomic tests aimed at addressing these challenges are costly and time-consuming, limiting widespread adoption.

Stratipath’s pioneer solution Stratipath Breast

Stratipath Breast is the first AI-based prognostic risk profiling tool, regulatory aligned for clinical use in the EU and the UK. The solution analyses cancer tissue, enabling the identification of patients with either an increased, or low risk of disease progression. It is already in clinical use and validated in large-scale studies, ensuring robust and reliable performance.

AI-based risk stratification enables faster turnaround times for results, provides new information at the point of diagnosis, and can reduce the need for expensive genomic testing, allowing for wider use and benefit to more patients. Stratipath Breast has been successfully implemented in clinical routine at multiple healthcare sites, where it is used daily for risk profiling of breast cancer patients.

Stratipath Breast provides healthcare providers with a faster, more affordable alternative to genomic tests, reducing both time to treatment and overall healthcare costs.

• Validated in large-scale external data sets
• In clinical use at several health care providers
• Integrated in existing diagnostic workflows
• Deep learning analysis of routine HE-stained histopathology images from resected breast cancer tumours
• Contributes to reduced costs, time and workload, facilitating broader use and more equal cancer care
• Rapid analysis for earlier treatment decisions
• Regulatory compliant for clinical use in the EU and the UK